Business Context and Reporting Period
SOPHiA GENETICS SA, a foreign private issuer based in Rolle, Switzerland, filed Form 6-K on January 12, 2026. The filing covers the month of January 2026 and provides preliminary unaudited financial results for the quarter and full year ended December 31, 2025.
Key Financial Metrics
The filing presents preliminary revenue and operational volume estimates. Specific figures for profit, cash flow, margins, debt, and liquidity are not provided in this text.
- Q4 2025 Revenue: Expected to be at least $21 million.
- Q4 2025 Analyses: Over 105,000 analyses performed on SOPHiA DDM.
- Full Year 2025 Revenue: Expected to be approximately $77 million.
- Full Year 2025 Analyses: Over 391,000 analyses performed on SOPHiA DDM (a new company record).
Material Changes Versus Prior Period
The Company reported significant year-over-year growth in both revenue and operational volume for the periods ended December 31, 2025:
- Q4 2025 Revenue Growth: Approximately 20% increase year-over-year.
- Q4 2025 Volume Growth: Approximately 16% increase in analyses year-over-year.
- Full Year 2025 Revenue Growth: Approximately 18% increase year-over-year.
Guidance, Outlook, and Management Commentary
Leadership Transition: The Company announced the promotion of Ross Muken to Chief Executive Officer, effective July 1, 2026. Mr. Muken, currently President, will succeed co-founder Dr. Jurgi Camblong. Dr. Camblong will transition to Executive Chairman of the Board, subject to election at the Annual General Meeting in June 2026.
Financial Uncertainty: The financial results presented are preliminary, unaudited, and inherently uncertain. The Company is completing its year-end close and review procedures. Final results may differ materially from these estimates as the Company prepares its consolidated financial statements. Independent auditors have not expressed an opinion on these preliminary figures.
Investor Verification Checklist
- Verify the final audited revenue and profit figures for Q4 and Full Year 2025 once the official financial statements are released.
- Confirm the exact date and outcome of Dr. Camblong's election as Executive Chairman at the June 2026 Annual General Meeting.
- Monitor subsequent filings for details on cash flow, debt levels, and liquidity, which were not disclosed in this preliminary report.
- Review the final count of SOPHiA DDM analyses to confirm the record-breaking status for 2025.